for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Predictive Oncology Inc

POAI.OQ

Latest Trade

1.00USD

Change

0.07(+7.69%)

Volume

374,097

Today's Range

0.91

 - 

1.01

52 Week Range

0.63

 - 

5.30

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.93
Open
0.93
Volume
374,097
3M AVG Volume
24.97
Today's High
1.01
Today's Low
0.91
52 Week High
5.30
52 Week Low
0.63
Shares Out (MIL)
24.09
Market Cap (MIL)
22.37
Forward P/E
--
Dividend (Yield %)
--

Next Event

Predictive Oncology Inc Annual Shareholders Meeting

Latest Developments

More

Predictive Oncology Reports Third Quarter 2020 Financial Results, Provides Business Update

Predictive Oncology- On Oct 14, Co Received Letter From Nasdaq Informing Co Does Not Comply With Minimum Closing Bid Price Requirement

Predictive Oncology Reports Qtrly Loss Per Share $0.36

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Predictive Oncology Inc

Predictive Oncology Inc. is focused on applying artificial intelligence (AI) to personalized medicine and drug discovery. It operates through its subsidiaries, Helomics Holding Corporation (Helomics), TumorGenesis Inc., Skyline Europe and Skyline Medical Inc. Helomics applies AI to its data gathered from patient tumors to both personalize cancer therapies for patients and focusses on the development of new-targeted therapies. Helomics’ clinical laboratory improvement amendments (CLIA)-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions. Its TumorGenesis Inc. is engaged in developing approach to tumors in the laboratory. Skyline Medical Inc. markets its STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions.

Industry

Medical Equipment & Supplies

Contact Info

2915 Commers Dr Ste 900

EAGAN, MN

55121-2363

United States

+1.651.3894800

http://www.precisiontherapeutics.com

Executive Leadership

Carl Schwartz

President, Chief Executive Officer, Director

Robert L Myers

Chief Financial Officer

David O. Johnson

Senior Vice President - Operations

J. Melville Engle

Director

H. Richard Gabriel

Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
17.13
Price To Book (MRQ)
1.26
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
47.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-161.42
Return on Equity (TTM)
-98.06

Latest News

Latest News

BRIEF-Predictive Oncology Files Prospectus Relating To Offer, Resale Of Up To 1.7 Million Shares

* PREDICTIVE ONCOLOGY FILES PROSPECTUS RELATES TO OFFER, RESALE OF UP TO 1.7 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS Source text (https://bit.ly/2NFewwm) Further company coverage:

BRIEF-Predictive Oncology Files Preliminary Prospectus Related To Offer And Resale Of Up To 3.3 Million Shares - SEC Filing

* PREDICTIVE ONCOLOGY INC FILES PRELIMINARY PROSPECTUS RELATED TO OFFER AND RESALE OF UP TO 3.3 MILLION SHARES OF COMMON STOCK - SEC FILING Source text for Eikon: https://bit.ly/2VeChQc Further company coverage:

BRIEF-Predictive Oncology's Tumorgenesis Division Secures First Commercial Sale Of Novel Ovarian Cancer Cell Media

* PREDICTIVE ONCOLOGY’S TUMORGENESIS DIVISION SECURES FIRST COMMERCIAL SALE OF ITS NOVEL OVARIAN CANCER CELL MEDIA Source text for Eikon: Further company coverage:

BRIEF-Predictive Oncology Files Prospectus Relates To Offer And Resale Of Up To 1.7 Million Shares Of Common Stock By Selling Stockholders

* PREDICTIVE ONCOLOGY INC FILES PROSPECTUS RELATES TO OFFER AND RESALE OF UP TO 1.7 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text - https://bit.ly/2BhvXAo Further company coverage:

BRIEF-Predictive Oncology Reports First Quarter 2020 Financial Results

* PREDICTIVE ONCOLOGY REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS, PROVIDES BUSINESS UPDATE

BRIEF-Predictive Oncology Enters Race To Develop A COVID-19 Vaccine

* PREDICTIVE ONCOLOGY (NASDAQ SYMBOL POAI) IS LICENSING AND PARTNERING THIS GROUNDBREAKING NSP10 TECHNOLOGY IN THE RACE TO DEVELOP A VACCINE FOR DEVELOPMENT Source text for Eikon: Further company coverage:

BRIEF-Predictive Oncology Announces $2.2 Mln Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

* PREDICTIVE ONCOLOGY ANNOUNCES $2.2 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

BRIEF-Predictive Oncology Files Prospectus Relates To Offer, Resale Of Up To 5.9 Mln Shares Of Common Stock By Selling Stockholders

* PREDICTIVE ONCOLOGY INC FILES PROSPECTUS RELATES TO OFFER, RESALE OF UP TO 5.9 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS Source: https://bit.ly/2RiUERX Further company coverage:

BRIEF-Predictive Oncology Reports 2019 Full-Year Financial Results

* PREDICTIVE ONCOLOGY REPORTS 2019 FULL-YEAR FINANCIAL RESULTS

BRIEF-Predictive Oncology - On March 19, Entered Into A Third Amendment To Amended And Restated Senior Secured Promissory Note Dated September 28, 2018

* PREDICTIVE ONCOLOGY INC - ON MARCH 19, ENTERED INTO A THIRD AMENDMENT TO AMENDED AND RESTATED SENIOR SECURED PROMISSORY NOTE DATED SEPTEMBER 28, 2018

BRIEF-Predictive Oncology Launches New AI Platform For Vaccine And Drug Development Targeting Coronaviruses And Acute Respiratory Syndromes

* PREDICTIVE ONCOLOGY LAUNCHES NEW AI PLATFORM FOR VACCINE AND DRUG DEVELOPMENT TARGETING CORONAVIRUSES AND ACUTE RESPIRATORY SYNDROMES (COVID-19, MERS, AND SARS)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up